ISSN (Online) - 2349-8846
-A A +A
Delivering Affordable Healthcare with Clot-buster Drugs

Economic Impact of Technology Interventions--Streptokinase

More than 20 lakh patients of ischaemic heart disease-led myocardial infarction can benefit from a life-saving clot-buster drug in India. At the turn of the century, its availability in India was poor and no domestic production existed until the first Council of Scientific and Industrial Research licensee began production in 2001-02. Its price was less than half that of the drug made by a multinational company, the major supplier in the market at that time. Its supply increased to 1,20,000 doses in 2011 after other producers entered the market. Prices dropped by more than 50%. The economic impact of streptokinase technologies, or the value that would be lost if the licensee's streptokinase did not exist, is about `580 crore for the patients.



 

Subscribers please login to access full text of the article.

 

 

Subscribe Now !

Get instant access to the complete EPW archives

New 3-Month Subscription to Digital Archives at just Rs 531 for India and $18 for overseas users.

  Subscribe  

Comments

(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Back to Top